Abstract: The present invention relates to a propellant-free aerosol formulation which contains one or more compounds of general formula 1, wherein the groups R1, R2, R3 and X? may have the meanings indicated in the claims and in the specification, and two further active substances 2 and 3, for inhalation.

Abstract: A pharmaceutical formulation, comprising: (a) a compound of formula 1 wherein: R1 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, or halogen; R2 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, or halogen; R3 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, halogen, OH, —O—C1-4-alkylene-COOH, or —O—C1-4-alkylene-COO—C1-4-alkyl; and X? denotes an anion with a single negative charge, or a tautomer, enantiomer, solvate, or hydrate thereof; (b) a second active substance 2 selected from tiotropium salts, oxitropium salts, flutropium salts, ipratropium salts, glycopyrronium salts, and trospium salts, or a tautomer, enantiomer, solvate, or hydrate thereof; (c) at least one pharmacologically acceptable acid; and (d) a solvent selected from water, ethanol, or a mixture of water and ethanol.

Abstract: A pharmaceutical formulation, comprising: (a) a compound of formula 1 wherein: R1 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, or halogen; R2 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, or halogen; R3 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, halogen, OH, —O—C1-4-alkylene-COOH, or —O—C14-alkylene-COO—C1-4-alkyl; and X? denotes an anion with a single negative charge, or a tautomer, enantiomer, solvate, or hydrate thereof; (b) a second active substance 2 selected from tiotropium salts, oxitropium salts, flutropium salts, ipratropium salts, glycopyrronium salts, and trospium salts, or a tautomer, enantiomer, solvate, or hydrate thereof. (c) at least one pharmacologically acceptable acid; and (d) a solvent selected from water, ethanol, or a mixture of water and ethanol.

Abstract: The present invention relates to a propellant-free aerosol formulation which contains one or more compounds of general formula 1, wherein the groups R1, R2, R3 and X? may have the meanings indicated in the claims and in the specification, and two further active substances 2 and 3, for inhalation.

Abstract: The present invention relates to a propellant-free aerosol formulation which contains one or more compounds of general formula 1, wherein the groups R1, R2, R3 and X? may have the meanings indicated in the claims and in the specification, and one other active substance 2, for inhalation.

Abstract: A pharmaceutical formulation, comprising: (a) a compound of formula 1 wherein: R1 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, or halogen; R2 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, or halogen; R3 is hydrogen, C1-4-alkyl, —O—C1-4-alkyl, halogen, OH, —O—C1-4-alkylene-COOH, or —O— C1-4-alkylene-COO—C1-4-alkyl; and X? denotes an anion with a single negative charge, or a tautomer, enantiomer, solvate, or hydrate thereof; (b) a second active substance 2 selected from tiotropium salts, oxitropium salts, flutropium salts, ipratropium salts, glycopyrronium salts, and trospium salts, or a tautomer, enantiomer, solvate, or hydrate thereof; (c) at least one pharmacologically acceptable acid; and (d) a solvent selected from water, ethanol, or a mixture of water and ethanol.